Intraocular Pressure Articles & Analysis
31 news found
Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high intraocular pressure. Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. ...
Current treatment for glaucoma focuses on reducing intraocular pressure to slow down the progression of the disease and prevent visual field loss. Common drugs for lowering intraocular pressure in glaucoma include adrenergic modulators, carbonic anhydrase inhibitors, and prostaglandin analogs. ...
The safety of aflibercept 8 mg in both trials was similar to the well-established safety profile of Eylea (aflibercept 2 mg) and consistent with previous clinical trials. The rates of intraocular inflammation and intraocular pressure increase for aflibercept 8 mg were low and similar to Eylea (aflibercept 2 mg). ...
ByBayer AG
The safety of aflibercept 8 mg in both trials was similar to the well-established safety profile of Eylea (aflibercept 2 mg) and consistent with previous clinical trials. The rates of intraocular inflammation (IOI) for aflibercept 8 mg compared to Eylea (aflibercept 2 mg) were 0.7% versus 0.6% in PULSAR and 0.8% versus 0.6% in PHOTON. ...
ByBayer AG
The safety of aflibercept 8 mg was consistent with the well-established safety profile of Eylea. Pre-injection intraocular pressure (IOP) values were similar to baseline values at all timepoints through week 48. Patients with IOP ≥ 35 mmHg pre- or post-injection at any timepoint for aflibercept 8 mg versus Eylea were 0.6% versus 0.3% in PULSAR and 0.2% versus ...
ByBayer AG
For the total group of Cohorts 1-4 (n=65), all common treatment emergent adverse events through 6 months in the study eye were mild or moderate and included conjunctival hemorrhage, increased intraocular pressure, episcleritis, and conjunctival hyperemia. Mild intraocular inflammation was reported at similar incidence in the first and second dose ...
Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, Clinique de Montchoisi, and an Adjoint Professor at the Department of Ophthalmology, University of Colorado School of Medicine (Denver, USA), he is an expert in the fields of minimally invasive glaucoma surgery (MIGS) and in intraocular pressure (IOP) monitoring. Prior to joining iSTAR ...
As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. ...
Marc Schargus (Asklepios Klinik Nord, Hamburg) will be presenting a meta-analysis from the STAR-I, STAR-II and STAR-III trials on patients with open-angle glaucoma who consistently achieve low diurnal intraocular pressures (IOP) of ≤18 mmHg up to two-years after implantation with MINIject. ...
In all three trials, MINIject® met all endpoints, which included a significant reduction in both intraocular pressure (IOP) as well as hypotensive medication-use. Furthermore, no safety concerns regarding corneal endothelial health were raised across all three trials, a pivotal factor in long-term safety. ...
The final study results demonstrated that canaloplasty and trabeculotomy performed as an implant-free minimally invasive glaucoma surgery (MIGS) using the OMNI® Surgical System in conjunction with cataract surgery significantly reduced unmedicated mean diurnal intraocular pressure (IOP), medication use and daily fluctuations in IOP in patients with open-angle ...
This innovative MIGS device, with its distinctive STAR material, provides a clear benefit to my patients to achieve the right balance of meaningful intraocular pressure reduction with favourable safety, sustained over the longer-term. ...
” 2022 ARVO Presentation Highlights Summary of Safety Results All 24 treated patients reported at least one adverse event (AE) and at least one ocular AE The majority of AEs reported with OpRegen were mild (Cohort 1-3, 87%; Cohort 4, 93%), and the immunosuppressive regimen was well tolerated Ocular AEs observed with OpRegen were mainly related to the surgical procedures used for ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
Patients who receive MIGS earlier in their disease management may benefit from less reliance on adherence to prescription eye drops, slowed progression of disease, improved management of intraocular pressure (IOP), and most importantly, sight preservation. “As optometrists, we are really in a unique position when it comes to glaucoma management, ...
MINIject has demonstrated meaningful and enduring intraocular pressure (IOP) reduction, combined with a favorable safety profile, in completed and ongoing trials conducted in Europe, the Americas and Asia in over 150 patients so far. ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. ...